​

Abbott Laboratories (ABT) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ABT Stock Forecast

Abbott Laboratories (ABT) stock forecast, based on 41 Wall Street analysts, predicts a 12-month average price target of $128.71, with a high of $152.00 and a low of $92.00. This represents a 38.62% increase from the last price of $92.85.

$90 $103 $116 $129 $142 $155 High: $152 Avg: $128.71 Low: $92 Last Closed Price: $92.85

ABT Stock Rating

Abbott Laboratories stock's rating consensus is Buy, based on 41 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 31 Buy (75.61%), 10 Hold (24.39%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 41 0 10 31 Strong Sell Sell Hold Buy Strong Buy

ABT Price Target Upside V Benchmarks

TypeNameUpside
StockAbbott Laboratories38.62%
SectorHealthcare Stocks 15.45%
IndustryMedical Device Stocks32.39%

Price Target Trends

1M3M12M
# Anlaysts5925
Avg Price Target$117.00$127.78$137.92
Last Closing Price$92.85$92.85$92.85
Upside/Downside26.01%37.62%48.54%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 266167--29
Mar, 266167--29
Feb, 266157--28
Jan, 266157--28
Dec, 256157--28
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Apr 22, 2026Daiwa$92.00$92.75-0.81%-0.92%
Apr 20, 2026Matt MiksicBarclays$143.00$96.8347.68%54.01%
Apr 17, 2026UBS$115.00$95.4620.47%23.86%
Apr 17, 2026Piper Sandler$115.00$95.4620.47%23.86%
Apr 17, 2026Stifel Nicolaus$120.00$95.4625.71%29.24%
Mar 13, 2026Danielle AntalffyUBS$158.00$108.4245.73%70.17%
Mar 13, 2026New Street$145.00$108.1434.09%56.17%
Feb 02, 2026Barclays$142.00$109.3029.92%52.93%
Jan 29, 2026Ilya ZubkovLoop Capital Markets$120.00$106.0913.11%29.24%
Jan 23, 2026Evercore ISI$138.00$108.6127.06%48.63%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Apr 22, 2026DaiwaNeutraldowngrade
Apr 20, 2026BarclaysOverweightOverweighthold
Mar 13, 2026UBSBuyBuyhold
Mar 13, 2026BenchmarkBuyBuyhold
Jan 23, 2026BTIGBuyBuyhold
Jan 23, 2026CitigroupBuyBuyhold
Jan 23, 2026Wells FargoOverweightOverweighthold
Jan 09, 2026BernsteinOutperformOutperformhold
Jan 05, 2026Evercore ISIOutperformOutperformhold
Jan 05, 2026BarclaysOverweightOverweighthold

Financial Forecast

EPS Forecast

$3 $4 $5 $6 $7 $8 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$3.97$3.94$3.30$7.67$3.74----
Avg Forecast$5.10$5.23$4.44$4.67$5.16$5.70$6.30$6.92$7.60
High Forecast$5.15$5.29$4.45$4.68$5.21$6.13$6.99$7.14$7.84
Low Forecast$5.05$5.16$4.43$4.66$5.08$5.49$5.55$6.82$7.49
Surprise %-22.16%-24.67%-25.68%64.24%-27.52%----

Revenue Forecast

$35B $40B $45B $50B $55B $60B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$43.08B$43.65B$40.11B$41.95B$44.33B----
Avg Forecast$42.32B$43.22B$40.08B$42.00B$44.38B$47.66B$51.09B$54.53B$58.49B
High Forecast$42.66B$43.58B$40.26B$42.08B$45.00B$48.69B$51.13B$55.85B$59.91B
Low Forecast$41.99B$42.75B$39.95B$41.87B$44.24B$47.22B$51.04B$53.94B$57.86B
Surprise %1.79%0.99%0.08%-0.12%-0.12%----

Net Income Forecast

$5B $6B $8B $10B $12B $14B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$7.07B$6.93B$5.72B$13.40B$6.52B----
Avg Forecast$5.75B$6.73B$5.70B$8.18B$8.99B$10.17B$10.96B$12.10B$13.29B
High Forecast$6.90B$8.07B$6.84B$8.19B$9.10B$10.72B$12.22B$12.48B$13.71B
Low Forecast$4.60B$5.38B$4.56B$8.16B$8.88B$9.61B$9.71B$11.93B$13.11B
Surprise %23.04%3.03%0.39%63.92%-27.44%----

ABT Forecast FAQ

Is Abbott Laboratories stock a buy?

Abbott Laboratories stock has a consensus rating of Buy, based on 41 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 31 Buy, 10 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Abbott Laboratories is a favorable investment for most analysts.

What is Abbott Laboratories's price target?

Abbott Laboratories's price target, set by 41 Wall Street analysts, averages $128.71 over the next 12 months. The price target range spans from $92 at the low end to $152 at the high end, suggesting a potential 38.62% change from the previous closing price of $92.85.

How does Abbott Laboratories stock forecast compare to its benchmarks?

Abbott Laboratories's stock forecast shows a 38.62% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the medical device stocks industry (32.39%).

What is the breakdown of analyst ratings for Abbott Laboratories over the past three months?

  • April 2026: 20.69% Strong Buy, 55.17% Buy, 24.14% Hold, 0% Sell, 0% Strong Sell.
  • March 2026: 20.69% Strong Buy, 55.17% Buy, 24.14% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 21.43% Strong Buy, 53.57% Buy, 25.00% Hold, 0% Sell, 0% Strong Sell.

What is Abbott Laboratories’s EPS forecast?

Abbott Laboratories's average annual EPS forecast for its fiscal year ending in December 2026 is $5.7, marking a 52.41% increase from the reported $3.74 in 2025. Estimates for the following years are $6.3 in 2027, $6.92 in 2028, and $7.6 in 2029.

What is Abbott Laboratories’s revenue forecast?

Abbott Laboratories's average annual revenue forecast for its fiscal year ending in December 2026 is $47.66B, reflecting a 7.51% increase from the reported $44.33B in 2025. The forecast for 2027 is $51.09B, followed by $54.53B for 2028, and $58.49B for 2029.

What is Abbott Laboratories’s net income forecast?

Abbott Laboratories's net income forecast for the fiscal year ending in December 2026 stands at $10.17B, representing an 55.82% increase from the reported $6.52B in 2025. Projections indicate $10.96B in 2027, $12.1B in 2028, and $13.29B in 2029.